POINT Biopharma Global Inc.
NASDAQ:PNT
12.5 (USD) • At close December 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2.79 | 4.866 | 9.457 | 226.58 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | -9,447.807 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.168 | 0 |
| Gross Profit
| 2.79 | 4.866 | 9,457.264 | 226.58 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.168 | 0 |
| Gross Profit Ratio
| 1 | 1 | 1,000 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 26.91 | 31.277 | 26.91 | 27.938 | 20.797 | 20.814 | 12.501 | 9.531 | 13.005 | 6.701 | 4.269 | 4.117 | 2.48 | 2.159 |
| General & Administrative Expenses
| 5.506 | 5.088 | 5.01 | 7.279 | 3.84 | 4.08 | 3.808 | 4.566 | 4.027 | 1.95 | 1.465 | 1.285 | 0.596 | 1.067 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.506 | 5.088 | 5.01 | 7.279 | 3.84 | 4.08 | 3.808 | 4.566 | 4.027 | 1.95 | 1.465 | 1.285 | 0.596 | 1.067 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 32.416 | 36.365 | 31.921 | 35.217 | 24.637 | 24.894 | 16.309 | 14.096 | 17.031 | 8.65 | 5.734 | 5.403 | 3.076 | 3.227 |
| Operating Income
| -29.626 | -31.499 | -22.463 | 191.362 | -24.637 | -24.894 | -16.309 | -14.096 | -17.031 | -8.65 | -5.734 | -5.403 | -3.076 | -3.227 |
| Operating Income Ratio
| -10.619 | -6.474 | -2.375 | 0.845 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 5.723 | 5.167 | 5.694 | 2.746 | 0.804 | 0.497 | 0.016 | -0.04 | 0.002 | -0.028 | -0.007 | -0.131 | 0.031 | 0.093 |
| Income Before Tax
| -23.903 | -26.332 | -16.769 | 194.108 | -23.833 | -24.397 | -16.292 | -14.136 | -17.036 | -8.681 | -5.744 | -5.537 | -3.047 | -3.134 |
| Income Before Tax Ratio
| -8.567 | -5.412 | -1.773 | 0.857 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.871 | -0.921 | -0.239 | 30.841 | 0.181 | 0.183 | 0.088 | 0.06 | 0.081 | 0.124 | 0.04 | 0.014 | 0 | 0.058 |
| Net Income
| -24.774 | -25.411 | -16.531 | 163.267 | -24.013 | -24.58 | -16.381 | -14.197 | -17.117 | -8.805 | -5.784 | -5.551 | -3.047 | -3.192 |
| Net Income Ratio
| -8.88 | -5.222 | -1.748 | 0.721 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.23 | -0.24 | -0.16 | 1.73 | -0.26 | -0.27 | -0.18 | -0.16 | -0.19 | -0.15 | -0.1 | -0.33 | -0.056 | -0.035 |
| EPS Diluted
| -0.23 | -0.24 | -0.16 | 1.7 | -0.26 | -0.27 | -0.18 | -0.16 | -0.19 | -0.15 | -0.1 | -0.33 | -0.056 | -0.035 |
| EBITDA
| -34.485 | -35.881 | -27.62 | 191.894 | -23.996 | -24.522 | -16.053 | -14.096 | -17.031 | -8.65 | -5.734 | -5.403 | -3.076 | -3.227 |
| EBITDA Ratio
| -12.36 | -7.374 | -2.92 | 0.847 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |